Market Overview

North America Conjugate Vaccine Market Report 2018 - Forecast to 2023 -


The "North
America Conjugate Vaccine Market (2018-2023)"
report has been
added to's offering.

The conjugate vaccine market in North America is expected to expand at a
CAGR of 3.2%, leading to a revenue of USD 16.26 Bn by 2023. By volume,
it is anticipated to reach 286.63 Million units by 2023 expanding at a
CAGR of 3%.

Conjugate vaccine is a type of vaccine that contains bacterial capsular
polysaccharide, attached with a protein to enhance immunogenicity and
protect against invasive diseases. North America is one of the most
prominent markets for conjugate vaccines.

Scheduled conjugated vaccinations, have eradicated health disparities
and consequently led to lower rate of disease incidence.

Market Segmentation:

  • Based on disease indication, the market is segmented into
    pneumococcal, haemophilus influenza type b,
    diphtheria-tetanus-pertussis, meningococcal and others. The highest
    penetration among paediatrics in North America was in the case of DTP
  • Based on end user, the market is segmented into pediatric and adult.
  • Based on countries, the market is divided into U.S. and Canada.

Key growth factors:

North America is projected to be one of the most significant markets for
conjugate vaccines during the forecast period, due to a rise in demand
for pneumococcal, meningococcal vaccines, and other conjugate vaccines.
Increased diagnosis and treatment are considered to fuel the North
American conjugate vaccine market. Recommended vaccines and dosages are
updated on a regular basis to comply with prevalent serogroups of
infectious agents. For example, the CDC has its own immunization
schedule for US citizens. This has increased the effectiveness of
administered vaccines, which thereby increases the demand for the
product, leading to increase in market sales.

Threats and key players:

  • The North America conjugate vaccine market is expected to grow
    positively. But since it is a saturated market, the scope for
    significant growth is limited. In North America, the population above
    65 years of age has decreased from 53,000,000 in 2014 to 51,900,000 in
    2016. So, the demand for adult vaccines has also reduced. The overall
    penetration rate for the adult segment is lower than that of the
    pediatric segment.
  • Major conjugate vaccine providers operating in the market are
    GlaxoSmithKline, Pfizer Inc., Merck, Novartis, Sanofi Pasteur, etc.

Companies Mentioned

  • GlaxoSmithKline
  • Pfizer Inc.
  • Merck & Co.
  • Novartis
  • Sanofi Pasteur
  • CSL Limited
  • Nuron Biotech Inc.

For more information about this report visit

View Comments and Join the Discussion!